XML 30 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Intangible Assets, Goodwill and Other
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure Goodwill and Other Intangible Assets
The changes in the carrying amount of goodwill by reportable segment for the years ended December 31, 2023 and 2022 were as follows:
Personal CareConsumer TissueK-C ProfessionalTotal
Balance at December 31, 2021$961 $494 $385 $1,840 
Acquisition304 — — 304 
Effect of foreign currency translation(60)(6)(4)(70)
Balance at December 31, 20221,205 488 381 2,074 
Divestiture— (4)(3)(7)
Effect of foreign currency translation9 7 2 18 
Balance at December 31, 2023$1,214 $491 $380 $2,085 
The carrying amounts of Other Intangible Assets, Net for the years ended December 31, 2023 and 2022 were as follows:
December 31
20232022
Gross Carrying Amount(b)
Accumulated Amortization(b)
Net Carrying Amount
Gross Carrying Amount(b)
Accumulated Amortization(b)
Net Carrying Amount
Intangible assets with indefinite lives:
Brand names$68 $— $68 $610 $— $610 
Intangibles assets with finite lives:
Trademarks and brand names148 (83)65 253 (91)162 
Other intangible assets(a)
76 (12)64 98 (19)79 
Total intangible assets with finite lives224 (95)129 351 (110)241 
Total$292 $(95)$197 $961 $(110)$851 
(a)    Other intangible assets primarily include customer and distributor relationships.
(b)    Amounts subject to foreign currency adjustments.
Amortization expense relating to the intangible assets with finite lives was $13, $15 and $9 for the three years ended December 31, 2023, 2022 and 2021, respectively. Based on the carrying values of the intangible assets with finite lives as of December 31, 2023, amortization expense for each of the next five years is estimated to be approximately $9.
In the second quarter of 2023, we conducted forecasting and strategic reviews and integration assessments of our Softex Indonesia business, acquired in the fourth quarter of 2020, and with performance below expectations since acquisition, we revised internal financial projections of the business to reflect updated expectations of future financial performance. These reviews and the subsequent revisions in the projections highlighted challenges for the Softex business arising from modified consumer shopping behavior in the post-COVID-19 period, inflationary pressures and other macroeconomic factors and increased competitive activity in the region. As a result of separate management reviews, we also have revised internal financial projections associated with our acquisition of a controlling interest in Thinx as a result of performance below expectations due to the impact of modified consumer shopping behavior in the post-COVID-19 period.
These revisions were considered triggering events requiring interim impairment assessments to be performed relative to the intangible assets that had been recorded as part of these acquisitions. These intangible assets were recorded as part of the Personal Care business segment and included indefinite-lived and finite-lived brands and finite-lived distributor and customer relationships. As a result of the interim impairment assessments, we recognized impairment charges, principally arising from the impairment charge of $593 related to the Softex business, totaling $658 pre-tax ($483 after tax) to write-down these intangible assets to their respective fair values aggregating to $188 as of June 30, 2023. The valuation methods used in the assessments included the relief from royalty and distributor and customer relationships methods. This noncash charge was included in Impairment of intangible assets in our consolidated income statement and in Asset impairments within Operating Activities in our consolidated cash flow statement.
We believe our estimates and assumptions used in the valuations are reasonable and comparable to those that would be used by other market participants; however, actual events and results could differ substantially from those used in the valuation, and to the extent such factors result in a failure to achieve the projected cash flows used to estimate fair value, additional noncash impairment charges could be required in the future.